IN2012DN01684A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01684A
IN2012DN01684A IN1684DEN2012A IN2012DN01684A IN 2012DN01684 A IN2012DN01684 A IN 2012DN01684A IN 1684DEN2012 A IN1684DEN2012 A IN 1684DEN2012A IN 2012DN01684 A IN2012DN01684 A IN 2012DN01684A
Authority
IN
India
Prior art keywords
malaria
malaria infection
mammal
compounds
transmission
Prior art date
Application number
Other languages
English (en)
Inventor
Xin-Zhuan Su
Jing Yuan
Dipak Raj
Sittiporn Pattaradilokrat
Ron Johnson
Ruili Huang
Original Assignee
U S A Represented By The Secretary Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S A Represented By The Secretary Dept Of Health And Human Services filed Critical U S A Represented By The Secretary Dept Of Health And Human Services
Publication of IN2012DN01684A publication Critical patent/IN2012DN01684A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
IN1684DEN2012 2009-08-27 2010-08-27 IN2012DN01684A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23741709P 2009-08-27 2009-08-27
PCT/US2010/047019 WO2011025969A1 (en) 2009-08-27 2010-08-27 Compounds that treat malaria and prevent malaria transmission

Publications (1)

Publication Number Publication Date
IN2012DN01684A true IN2012DN01684A (enExample) 2015-06-05

Family

ID=43628406

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1684DEN2012 IN2012DN01684A (enExample) 2009-08-27 2010-08-27

Country Status (6)

Country Link
US (2) US9375424B2 (enExample)
EP (1) EP2470013A4 (enExample)
CN (1) CN102595894A (enExample)
CA (1) CA2772085A1 (enExample)
IN (1) IN2012DN01684A (enExample)
WO (1) WO2011025969A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
WO2013082469A2 (en) * 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014031872A2 (en) * 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
WO2017050297A1 (en) * 2015-09-25 2017-03-30 Sun Jet Biotechnology Inc. Combination therapy for ev71 infection
EP3416972A1 (en) 2016-02-19 2018-12-26 Council of Scientific & Industrial Research Silicon based cyclic compounds and pharmaceutical compositions for treating malaria and toxoplasmosis
GB2587951B (en) 2018-04-26 2023-03-08 Cas Lamvac Guangzhou Biomedical Tech Co Ltd Attenuation system and use thereof
CN116987040B (zh) * 2023-06-21 2025-09-23 中国中医科学院中药研究所 二苯并二氮杂卓衍生物及其制备方法和应用
CN117064888A (zh) * 2023-09-26 2023-11-17 中国科学院水生生物研究所 氯喹或其药学上可接受的盐在制备预防生产非整倍体配子的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373005A (en) 1988-04-20 1994-12-13 Merrell Dow Pharmaceuticals Inc. Despiramine in the treatment of drug-resistant malarial infections
US5853739A (en) * 1988-05-02 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Transmission-blocking vaccine against malaria
DE3821392A1 (de) * 1988-06-24 1989-12-28 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen)
US5021426A (en) 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
CA2192203A1 (en) 1994-06-17 1995-12-28 Werner Hofheinz N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
WO2002011757A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting transmission of malaria
US6881841B2 (en) 2000-11-22 2005-04-19 Tsutomu Takeuchi Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives
US7670631B2 (en) * 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
TW200615273A (en) 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
WO2008064011A1 (en) 2006-11-13 2008-05-29 The Government Of The U.S. Of America As Represented By The Department Of Veterans Affairs Acridone compounds
WO2009026858A1 (es) 2007-08-28 2009-03-05 Centro De Quimica Farmaceutica Derivados de la acridinona como agentes antiparasitarios, antifungicos y antivirales.

Also Published As

Publication number Publication date
US20120196882A1 (en) 2012-08-02
US9375424B2 (en) 2016-06-28
CA2772085A1 (en) 2011-03-03
EP2470013A1 (en) 2012-07-04
EP2470013A4 (en) 2013-05-01
US20160303103A1 (en) 2016-10-20
WO2011025969A1 (en) 2011-03-03
CN102595894A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
EA201200355A1 (ru) Способы предотвращения и лечения ишемии головного мозга
IN2012DN00624A (enExample)
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
NZ703064A (en) Inhibitors of hepatitis c virus
WO2010057101A3 (en) Compounds useful as hiv blockers
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
UA116765C2 (uk) (гетеро)арилциклопропіламіни як інгібітори lsd1
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
SG179082A1 (en) Method for the preparation of an influenza virus
SG178952A1 (en) Chemical compounds
MY161495A (en) Virus like particle compositions and methods of use
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
IN2012DN00971A (enExample)
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MX2014015884A (es) Compuestos antivirales.
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
EP2538970A4 (en) TREATMENT OR PREVENTION OF INFECTION
MY172788A (en) Influenza vaccines
NZ610547A (en) Novel monensin derivatives for the treatment and prevention of protozoal infections
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.